Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.
A patient with chronic schizophrenia treated with fluphenazine developed neuroleptic malignant syndrome, characterized by fever, obtundation, rigidity, and tremulousness. Hyperthermia and elevated serum creatine kinase were successfully corrected by parenteral treatment with dantrolene. Obtundation, rigidity, and tremulousness responded to high doses of bromocriptine.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use*; D003620:Dantrolene / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005476:Fluphenazine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*
D001971:Bromocriptine; D003620:Dantrolene; C011825:fluphenazine depot; D005476:Fluphenazine